Our main hypothesis was that high-intensity statin treatment of statin-naïve early-onset STEMI patients decreased serum CoQ10 levels and this secondary CoQ10 deficiency was correlated with an increased level of fatty acid-binding protein-3 (FABP3), a sensitive and specific biomarker of myopathy. This evidence concerns the gene FABP3 and myopathy.